J. Patel, R. Anderson, E. Rappaport
May 1, 1999
Citations
5
Influential Citations
179
Citations
Quality indicators
Journal
Diabetes
Abstract
Aim: Rosiglitazone is the most potent of the thiazolidinediones, a novel class of oral antidiabetic agents that reduce blood glucose levels by sensitizing peripheral tissues to insulin. This study was designed to identify doses of rosiglitazone that would lower fasting plasma glucose (FPG) in patients with type 2 diabetes.